A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is study designed to investigate the efficacy and safety of Jaktinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index (PASI) score and routine safety assessments.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Criteria

Inclusion Criteria:

• 18~65 years old (including lower limit), no gender limit；

• You must have active chronic plaque psoriasis for at least 6 months prior to entry into the study；

• You must have active plaque psoriasis covering at least 10% body surface area； You must have Psoriasis Area and Severity Index (PASI) score of at least 12；You must have Static Physician's Global Assessment (sPGA) score of at least 3；

• The patient can communicate well with the investigator and follow the research and follow-up procedures；

• Understand and voluntarily sign the informed consent form.

Exclusion Criteria:

• You must not have prior treatment with an oral Janus kinase (JAK) inhibitor；

• You must not have received a phototherapy within 4 weeks prior to entry into the study；

• You must not have a history of active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)；

• You must not have a history of chronic alcohol abuse or intravenous (IV) drug abuse